• PDF: Delivered by email usually within 48 UK business hours.

Sigma-Aldrich Corporation (SIAL) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:111

Sigma-Aldrich Corporation (SIAL) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Sigma-Aldrich Corporation (SIAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Sigma-Aldrich Corporation (Sigma-Aldrich) is a life science and high technology company engaged in the development, manufacture, purchase and distribution of a wide variety of high quality biochemicals and organic chemicals. These chemical products and kits are used in scientific, genomic and proteomic research, biotechnology, and pharmaceutical development, and also as key components in pharmaceutical and other high technology manufacturing industries. The company operates globally in 38 countries and provides about 130,000 chemical products, out of which 48,000 are manufactured by the company. Sigma-Aldrich caters to the needs of people in 160 countries through its wide network of subsidiaries. The company is headquartered in Missouri, the US.

Sigma-Aldrich Corporation (SIAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

This report covers the following industry codes:
SIC Code: 2835
NAICS Code: 325413

  • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • Sigma-Aldrich Acquires Electrophoresis Business Of NextGen Sciences
    • Sigma-Aldrich Acquires Seppro Depletion Technology From GenWay Biotech
    • Sigma-Aldrich Acquires Iropharm A Unit Of Honeywell
    • Venture Financing
    • Cedarburg Pharmaceuticals Raises $3.5 Million In Series A-3 Financing
    • GenoSpectra Raises $12.2 Million In Series C Financing
    • Proteome Sciences Enters Into License Agreement With Sigma-Aldrich
    • Sigma-Aldrich Signs Licensing Agreement With Epigentek Group
    • Sigma-Aldrich Signs Licensing Agreement With Rubicon Genomics
    • Fluorotechnics Enters Into Licensing Agreement With Sigma-Aldrich
    • Partnerships
    • BASF Enters Into Distribution Agreement With Sigma-Aldrich
    • Domainex Enters Into Collaboration With Sigma-Aldrich
    • SAFC Pharma Expands Its Distribution Agreement With Novozymes Biopharma
    • Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands
    • Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim
    • Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer
    • Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals
    • Sigma-Aldrich Enters Into Distribution Agreement With Stemgent
    • Sigma-Aldrich Signs Distribution Agreement With ThalesNano Nanotechnology
    • BioLife Solutions Enters Into Distribution Agreement With Sigma-Aldrich
    • Cherokee Pharmaceuticals Enters Into An Agreement With SAFC Pharma
    • Sigma-Aldrich Enters Into Collaboration With Roche NimbleGen
    • Sigma-Aldrich Enters Into An Agreement With MitoProd
    • Sigma-Aldrich Signs An Agreement With CPC Scientific
    • Sigma-Aldrich Enters Into An Agreement With D-Finitive Cell Technologies
    • Sigma-Aldrich Enters Into An Agreement With AlphaGenix
    • Sigma-Aldrich Enters Into An Agreement With IsoSciences
    • Sigma-Aldrich Enters Into Co-Development Agreement With UCSF
    • Sigma-Aldrich Signs An Agreement With Plextronics
    • Sigma-Aldrich Enters Into An Agreement With MorphoSys
    • Atlas Antibodies Enters Into Distribution Agreement With Sigma-Aldrich
    • Chiral Quest Enters Into Co-Marketing Agreement With Sigma-Aldrich
    • Sangamo BioSciences Enters Into An Agreement With Sigma-Aldrich
    • Supelco signs distribution agreement with MIP Technologies
    • Oxford BioMedica Enters Into Co-Marketing Agreement With Sigma-Aldrich
    • Sigma-Aldrich Enters Into An Agreement With MedAssets
    • Sigma-Aldrich Enters Into Agreement With SiGNa Chemistry
    • Sigma-Aldrich Enters Into Agreement With Reaxa
    • Sigma-Aldrich Enters Into An Agreement Corning Life Sciences
    • Sigma-Aldrich Enters Into An Agreement With Cyntellect
    • Licensing Agreements
    • Sigma-Aldrich Enters Into Licensing Agreement With CSIRO
    • Oxford BioMedica And Sigma-Aldrich Enters Into Agreement With Biotechnology Company
    • Sigma-Aldrich Enters Into An Agreement With Pfizer
    • Sigma-Aldrich And Oxford BioMedica Enter Into An Agreement With GlaxoSmithKline
    • Plasticell Enters Into Licensing Agreement With Sigma-Aldrich
    • Allozyne Enters Into Licensing Agreement With Sigma-Aldric
    • University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich
    • Sigma-Aldrich Enters Into Licensing Agreement With Polyplus-transfection
    • Sigma-Aldrich Expands Licensing Agreement With Sangamo BioSciences
    • University Of Illinois Enters Into Licensing Agreement With Sigma-Aldrich
    • Sangamo BioSciences And Sigma-Aldrich Signs An Agreement With Roche
    • Sigma-Aldrich Enter Into Agreement With Rosetta Inpharmatics
    • Sigma-Aldrich Enters Into Licensing Agreement With Rubicon Genomics
    • Sigma-Aldrich Enters Into An Agreement With Genospectra
    • Sigma-Aldrich Enters Into An Agreement With Benitec
    • Sigma-Aldrich Enters Into Licensing Agreement With Rubicon Genomics
    • Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich
    • Equity Offering
    • Oxford BioMedica Completes Private Placement Of $53 Million
    • Divestiture - Company
    • Affymetrix Acquires Panomics
    • Debt Offering
    • Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For $300 Million
    • Sigma-Aldrich Completes Offering Of 5.11% Series 2006-A Senior Notes For $100 Million
    • Acquisition
    • Sigma-Aldrich Acquires Resource Technology
    • Sigma-Aldrich Acquires Cerilliant From Argenta Partners
    • Sigma-Aldrich Acquires ChemNavigator
    • Sigma-Aldrich Acquires Molecular Medicine Bioservices
    • Sigma-Aldrich Acquires Epichem Group
    • Sigma-Aldrich Acquires Advanced Separation Technologies
    • Sigma-Aldrich Acquires Pharmorphix
    • Sigma-Aldrich Acquires Stake In Benitec
    • Sigma-Aldrich Acquires Beijing Superior Chemicals and Instruments Company
    • Sigma-Aldrich Acquires Stake In Oxford BioMedica
    • Sigma-Aldrich Acquires Proligo From Degussa
    • Sigma-Aldrich Acquires JRH Biosciences From CSL
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Strategy And Business Planning
    • Nov 10, 2009: Sigma-Aldrich Seals Distribution Agreement With Stemgent
    • Nov 03, 2009: Sigma-Aldrich Enters into Agreement With Polyplus-transfection to Offer ZNA Oligonucleotides
    • Oct 05, 2009: Sigma-Aldrich, Sangamo Extend License Agreement
    • Financial Announcements
    • Oct 21, 2010: Sigma-Aldrich Reports Net Income Of $93 Million For Q3 2010
    • Research And Development
    • Nov 15, 2010: Domainex Collaborates With Sigma-Aldrich Corporation To Advance Study Of Epigenetic Proteins
    • Corporate Communications
    • Feb 16, 2011: Sigma-Aldrich Announces Senior Management Changes
    • Nov 15, 2010: Sigma-Aldrich Names Kirk Richter As Interim CFO
    • Nov 14, 2010: Sigma-Aldrich Names Rakesh Sachdev As President And CEO
    • Aug 18, 2010: Sigma-Aldrich Appoints Magnus Borg As Vice President And Chief Information Officer
    • May 14, 2010: Sigma-Aldrich Announces Executive Management Changes
    • Product News
    • Jul 23, 2009: OMT Presents Breakthrough In Novel Human Antibody Platform Development
    • Jun 23, 2009: Sigma-Aldrich And Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies
    • May 24, 2000: Medix Resources Site Growing In Popularity
    • Other Significant Developments
    • Apr 08, 2010: Sigma-Aldrich Signs New Distribution Agreement With Boehringer Ingelheim
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 111
  • List of Tables
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Key Facts, 2009
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Deals By Therapy Area, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Medical Devices Deals, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Sigma-Aldrich Acquires Electrophoresis Business Of NextGen Sciences
    • Sigma-Aldrich Acquires Seppro Depletion Technology From GenWay Biotech
    • Sigma-Aldrich Acquires Iropharm A Unit Of Honeywell
    • Cedarburg Pharmaceuticals Raises $3.5 Million In Series A-3 Financing
    • GenoSpectra Raises $12.2 Million In Series C Financing
    • Proteome Sciences Enters Into License Agreement With Sigma-Aldrich
    • Sigma-Aldrich Signs Licensing Agreement With Epigentek Group
    • Sigma-Aldrich Signs Licensing Agreement With Rubicon Genomics
    • Fluorotechnics Enters Into Licensing Agreement With Sigma-Aldrich
    • BASF Enters Into Distribution Agreement With Sigma-Aldrich
    • Domainex Enters Into Collaboration With Sigma-Aldrich
    • SAFC Pharma Expands Its Distribution Agreement With Novozymes Biopharma
    • Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands
    • Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim
    • Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer
    • Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals
    • Sigma-Aldrich Enters Into Distribution Agreement With Stemgent
    • Sigma-Aldrich Signs Distribution Agreement With ThalesNano Nanotechnology
    • BioLife Solutions Enters Into Distribution Agreement With Sigma-Aldrich
    • Cherokee Pharmaceuticals Enters Into An Agreement With SAFC Pharma
    • Sigma-Aldrich Enters Into Collaboration With Roche NimbleGen
    • Sigma-Aldrich Enters Into An Agreement With MitoProd
    • Sigma-Aldrich Signs An Agreement With CPC Scientific
    • Sigma-Aldrich Enters Into An Agreement With D-Finitive Cell Technologies
    • Sigma-Aldrich Enters Into An Agreement With AlphaGenix
    • Sigma-Aldrich Enters Into An Agreement With IsoSciences
    • Sigma-Aldrich Enters Into Co-Development Agreement With UCSF
    • Sigma-Aldrich Signs An Agreement With Plextronics
    • Sigma-Aldrich Enters Into An Agreement With MorphoSys
    • Atlas Antibodies Enters Into Distribution Agreement With Sigma-Aldrich
    • Chiral Quest Enters Into Co-Marketing Agreement With Sigma-Aldrich
    • Sangamo BioSciences Enters Into An Agreement With Sigma-Aldrich
    • Supelco signs distribution agreement with MIP Technologies
    • Oxford BioMedica Enters Into Co-Marketing Agreement With Sigma-Aldrich
    • Sigma-Aldrich Enters Into An Agreement With MedAssets
    • Sigma-Aldrich Enters Into Agreement With SiGNa Chemistry
    • Sigma-Aldrich Enters Into Agreement With Reaxa
    • Sigma-Aldrich Enters Into An Agreement Corning Life Sciences
    • Sigma-Aldrich Enters Into An Agreement With Cyntellect
    • Sigma-Aldrich Enters Into Licensing Agreement With CSIRO
    • Oxford BioMedica And Sigma-Aldrich Enters Into Agreement With Biotechnology Company
    • Sigma-Aldrich Enters Into An Agreement With Pfizer
    • Sigma-Aldrich And Oxford BioMedica Enter Into An Agreement With GlaxoSmithKline
    • Plasticell Enters Into Licensing Agreement With Sigma-Aldrich
    • Allozyne Enters Into Licensing Agreement With Sigma-Aldric
    • University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich
    • Sigma-Aldrich Enters Into Licensing Agreement With Polyplus-transfection
    • Sigma-Aldrich Expands Licensing Agreement With Sangamo BioSciences
    • University Of Illinois Enters Into Licensing Agreement With Sigma-Aldrich
    • Sangamo BioSciences And Sigma-Aldrich Signs An Agreement With Roche
    • Sigma-Aldrich Enter Into Agreement With Rosetta Inpharmatics
    • Sigma-Aldrich Enters Into Licensing Agreement With Rubicon Genomics
    • Sigma-Aldrich Enters Into An Agreement With Genospectra
    • Sigma-Aldrich Enters Into An Agreement With Benitec
    • Sigma-Aldrich Enters Into Licensing Agreement With Rubicon Genomics
    • Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich
    • Oxford BioMedica Completes Private Placement Of $53 Million
    • Affymetrix Acquires Panomics
    • Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For $300 Million
    • Sigma-Aldrich Completes Offering Of 5.11% Series 2006-A Senior Notes For $100 Million
    • Sigma-Aldrich Acquires Resource Technology
    • Sigma-Aldrich Acquires Cerilliant From Argenta Partners
    • Sigma-Aldrich Acquires ChemNavigator
    • Sigma-Aldrich Acquires Molecular Medicine Bioservices
    • Sigma-Aldrich Acquires Epichem Group
    • Sigma-Aldrich Acquires Advanced Separation Technologies
    • Sigma-Aldrich Acquires Pharmorphix
    • Sigma-Aldrich Acquires Stake In Benitec
    • Sigma-Aldrich Acquires Beijing Superior Chemicals and Instruments Company
    • Sigma-Aldrich Acquires Stake In Oxford BioMedica
    • Sigma-Aldrich Acquires Proligo From Degussa
    • Sigma-Aldrich Acquires JRH Biosciences From CSL
    • Sigma-Aldrich Corporation, Key Employees
    • Sigma-Aldrich Corporation, Subsidiaries 103
  • List of Figures
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Sigma-Aldrich Corporation, Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Sigma-Aldrich Corporation (SIAL) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha